Latest filing published 24 Sept 2026 for Theravance Biopharma, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Brett A. Grimaud discloses dealings in Theravance Biopharma, Inc. to SEC (Form 4). In total, 21 filings cover trades dated from 20 February 2023 to 23 September 2026.
Not one of the filings records a straightforward purchase or sale on the market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Most recently, on 24 September 2026, the filings show a transaction in Theravance Biopharma, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
21 of 21 declarations